This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. - 187. (Canceled)

- 188. (New) A method of suppressing spermatogenesis, inducing azospermia and/or inducing oligospermia in a male, comprising: i) administering to the male an effective amount of a testosterone ester by intramuscular injection, subcutaneous implantation, or subcutaneous injection; and, ii) administering to the male an effective amount of a norethisterone modified at the 17-hydroxyl group to an ether, carboxylic ester, silyl, phosphate, sulfonate or sulfate, which possesses both androgenic and estrogenic properties.
- 189. (New) The method of claim 188, wherein the testosterone ester and norethisterone are administered separately.
- 190. (New) The method of claim 189, wherein the norethisterone is administered by intramuscular injection, intravenous injection, subcutaneous implantation, subcutaneous injection or transdermally.
- 191. (New) The method according to claim 189, wherein the injection or implantation of the testosterone ester is in intervals of not less than 6 weeks.

- 192. (New) The method according to claim 191, wherein the dose of testosterone ester provides a dose of testosterone ranging between 500 and 1200 mg for a 6-week administration.
- 193. (New) The method according to claim 191, wherein the testosterone ester is testosterone undecanoate and the dose of testosterone undecanoate ranges between 800 and 1500 mg for a 6-week administration.
- 194. (New) The method according to claim 191, wherein the testosterone ester is testosterone undecanoate and the dose of testosterone undecanoate is 1000 mg for a 6-week administration.
- 195. (New) The method of claim 188, wherein the testosterone ester and norethisterone are administered together by intramuscular injection, subcutaneous implantation, or subcutaneous injection.
- 196. (New) The method according to claim 195, wherein the injection or implantation of the testosterone ester and norethisterone is in intervals of not less than 6 weeks.
- 197. (New) The method according to claim 195, wherein the injection or implantation of the testosterone ester and norethisterone is in intervals of not less than 8 weeks.

- 198. (New) The method according to claim 195, wherein the injection or implantation of the testosterone ester and norethisterone is in intervals of not less than 10 weeks.
- 199. (New) The method according to claim 195, wherein the dose of testosterone ester provides a dose of testosterone ranging between 500 and 1200 mg for a 6-week administration.
- 200. (New) The method according to claim 195, wherein the testosterone ester is testosterone undecanoate and the dose of testosterone undecanoate ranges between 800 and 1500 mg for a 6-week administration.
- **201.** (New) The method according to claim 195, wherein the testosterone ester is testosterone undecanoate and the dose of testosterone undecanoate is 1000 mg for a 6-week administration.
- 202. (New) The method according to claim 188, wherein the modified norethisterone is administered such that a daily release of a modified norethisterone in an amount between 1 and 10 mg is provided.
- 203. (New) The method according to claim 188, wherein the modified norethisterone is a carboxylic ester of norethisterone.

- **204.** (New) The method according to claim 203, wherein the carboxylic ester of norethisterone is an acetate ester and/or an enanthate ester.
- 205. (New) The method according to claim 203, wherein the carboxylic ester of norethisterone is norethisterone enanthate.
- 206. (New) The method according to claim 188, wherein the amount of said modified norethisterone and said testosterone ester provides effective levels of said modified norethisterone and said testosterone ester in the circulation for not less than 6 weeks.
- 207. (New) The method according to claim 206, wherein the dose of modified norethisterone is between 100 and 500 mg.
- 208. (New) The method according to claim 206, wherein the dose of modified norethisterone is between 200 and 400 mg.
- 209. (New) The method according to claim 206, wherein the effective levels in the circulation are sustained for not less than 10 weeks.
- 210. (New) The method according to claim 188, wherein the testosterone ester is selected from the group consisting of testosterone propionate, testosterone undecanoate, testosterone enanthate, testosterone cypionate and testosterone buciclate.

- 211. (New) The method according to claim 188, wherein the testosterone ester is testosterone undecanoate.
- 212. (New) The method according to claim 188, wherein the testosterone ester is administered such that a daily release of testosterone in an amount ranging between 5 and 35 mg is provided.
- 213. (New) The method according to claim 188, wherein the testosterone ester is administered such that a daily release of testosterone in an amount ranging between 15 and 30 mg is provided.
- 214. (New) The method according to claim 211, wherein the dose of testosterone undecanoate provides a dose of testosterone ranging between 500 and 1200 mg for a 6-week administration.
- 215. (New) The method according to claim 211, wherein the dose of testosterone undecanoate ranges between 800 and 1500 mg for a 6-week administration.
- **216.** (New) The method according to claim 211, wherein testosterone undecanoate is in a dose of 1000 mg for a 6-week administration.
- 217. (New) The method according to claim 188, wherein said modified norethisterone and testosterone ester are both administered by intramuscular injection, or subcutaneous implant.

- 218. (New) The method according to claim 188, wherein said modified norethisterone and testosterone ester are both administered by intramuscular injection.
- 219. (New) The method of claim 189, wherein the testosterone ester is administered by intramuscular injection and the norethisterone is administered by transdermal patch.
- 220. (New) The method according to claim 188, which is effective for male contraception.